A collaboration over four gene therapy programmes substantially beefs up Neurocrine’s pipeline, while Voyager Therapeutics gets a much-needed infusion of credibility.
Neurocrine Biosciences is hoping to untick the box on its previous Tourette’s failures, while Redhill hopes that it has the Talicia keys.
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
If the US drugs regulator picks up the pace in the second half of the year, 2018 could be a bumper year for novel medicine approvals.
No slowdown at the FDA, as regulator remains on track to approve at least 43 new drugs this year.